Eli Lilly’s weight-loss drug tirzepatide has received approval in China
Eli Lilly said in a social media post Friday its weight-loss drug tirzepatide won approval from Chinese regulators, further boosting competition with Danish rival Novo Nordisk in the key Asian market.
BELIEBTE BEITRÄGE
Portugal declares risk as wildfires hit the north of the country
September 17, 2024
UK to appoint nature envoy
September 17, 2024
Death tolls rises as Central Europe floods
September 17, 2024
LIVEÜBERTRAGUNG